tmem35a Antibody

What is the optimal application for TMEM35A antibodies in neurological research?

Western Blot (WB) represents the most widely validated application for TMEM35A antibodies, with ELISA serving as another common method . For neurological investigations specifically, researchers should consider:

The subcellular localization of TMEM35A in peroxisomes and ER makes careful sample preparation crucial when designing experiments .

How do I select the appropriate TMEM35A antibody for cross-species comparative studies?

When conducting evolutionary or comparative studies across species, antibody selection requires careful consideration:

• Examine the documented reactivity profile of each antibody candidate. Multiple commercial antibodies demonstrate cross-reactivity with human, mouse, rat, bovine, dog, guinea pig, and even zebrafish TMEM35A

• Target conserved epitopes, such as antibodies directed against the C-terminal region (aa 120-167), which may offer broader cross-species recognition

• Validate each antibody empirically in your species of interest before conducting full experiments

• For novel species comparisons, consider multiple antibodies targeting different epitopes to confirm findings

• Ensure sequence homology in the targeted region across your species of interest

Remember that TMEM35A gene orthologs have been reported in mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken species, providing various comparative research opportunities .

What are the key considerations for validating a TMEM35A antibody before experimental use?

Thorough validation is essential before proceeding with experiments:

• Employ positive controls such as TMEM35A overexpression lysates from HEK293T cells, which are available commercially

• Include negative controls such as tissues known not to express TMEM35A or knockout models

• Verify the appropriate molecular weight detection (approximately 18.4 kDa for human TMEM35A)

• Perform titration experiments to determine optimal antibody concentration

• For applications beyond Western blotting, validate specificity in each experimental context separately

• Consider independent validation with multiple antibodies targeting different epitopes

• Evaluate batch-to-batch consistency when purchasing the same antibody over time

How might TMEM35A antibody selection differ when studying its role in nicotinic acetylcholine receptor regulation versus other cellular functions?

The antibody selection strategy should align with your specific research question:

• For nAChR regulation studies: Select antibodies targeting epitopes unlikely to be masked when TMEM35A is complexed with nAChRs. Consider membrane extraction protocols that preserve protein-protein interactions

• For subcellular localization studies: Choose antibodies validated for immunocytochemistry that can distinguish between peroxisomal and ER localization

• For protein interaction studies: Select antibodies that won't disrupt native protein complexes if conducting co-immunoprecipitation experiments

• For quantitative expression analysis: Use antibodies with linear detection ranges in Western blot applications

When studying TMEM35A as the molecular chaperone NACHO (one of its synonyms), focus on antibodies that specifically recognize functional domains involved in nAChR assembly .

What are the challenges in detecting TMEM35A in specific brain regions, and how can they be overcome?

Brain tissue analysis presents several technical challenges:

• Low abundance issue: TMEM35A may be expressed at varying levels across different brain regions, necessitating sensitive detection methods

• Signal specificity: Despite notable expression in hippocampus, cerebral cortex, cerebellum, and caudate, background signal can complicate interpretation

• Sample preparation: Optimize tissue fixation and membrane protein extraction specifically for TMEM35A detection

• Antigen retrieval: Implement specialized protocols for transmembrane proteins to expose epitopes while maintaining tissue architecture

• Signal amplification: Consider tyramide signal amplification or similar techniques for low-abundance detection

• Controls: Include brain-region-specific positive and negative controls with every experiment

Compare antibody performance across multiple techniques (IHC, IF, WB) to build confidence in regional expression patterns.

How do post-translational modifications of TMEM35A affect antibody recognition, and how can this impact experimental interpretation?

Post-translational modifications may significantly influence experimental outcomes:

• Epitope masking: Modifications can directly block antibody binding sites or alter protein conformation

• Migration pattern changes: Modified TMEM35A may deviate from the predicted 18.4 kDa molecular weight in SDS-PAGE

• Detection strategy: Use multiple antibodies targeting different epitopes to identify discrepancies suggesting modifications

• Specialized techniques: Consider phospho-specific or glyco-specific detection methods if these modifications are suspected

• Sample preparation: Include phosphatase or glycosidase treatments as controls to identify modification-dependent recognition patterns

• Experimental conditions: Cellular stress, differentiation state, or disease models may alter TMEM35A modification patterns

Researchers should document any unexpected banding patterns and investigate whether they represent physiologically relevant TMEM35A variants.

What protocol optimizations are recommended for Western blot detection of TMEM35A in brain tissue lysates?

For optimal Western blot results:

• Sample preparation: Use modified RIPA buffer (25mM Tris-HCl pH7.6, 150mM NaCl, 1% NP-40, 1mM EDTA) with protease inhibitor cocktail, PMSF, and Na₃VO₄ as described for TMEM35A lysate preparation

• Protein loading: Load 20-40 μg of total protein per lane for brain tissue lysates

• Gel selection: Use higher percentage (12-15%) gels for better resolution of the small 18.4 kDa protein

• Transfer conditions: Implement low molecular weight-optimized transfer parameters (lower voltage for longer time)

• Blocking: Use 5% BSA rather than milk to reduce background

• Antibody incubation: Extended overnight incubation at 4°C may improve signal-to-noise ratio

• Detection: Consider enhanced chemiluminescence or fluorescent secondary antibodies for optimal sensitivity

• Controls: Include recombinant TMEM35A or overexpression lysates as positive controls

How can co-immunoprecipitation be optimized to study TMEM35A interactions with nicotinic acetylcholine receptors?

For successful co-immunoprecipitation studies:

• Lysis conditions: Use gentle non-ionic detergents (0.5-1% NP-40) to preserve protein-protein interactions

• Buffer composition: Consider the buffer described for HEK293T lysate preparation (25mM Tris-HCl pH7.6, 150mM NaCl, 1% NP-40, 1mM EDTA with protease inhibitors)

• Antibody selection: Choose antibodies that don't target interaction interfaces between TMEM35A and nAChRs

• Pre-clearing: Remove non-specific binding proteins by pre-incubation with beads alone

• Incubation parameters: Extend interaction time (overnight at 4°C) to capture even weak or transient associations

• Washing stringency: Balance between removing non-specific interactions while preserving specific ones

• Elution conditions: Consider native elution with competing peptides for downstream functional studies

• Controls: Include IgG controls, input controls, and reciprocal IPs (pull down with anti-nAChR and blot for TMEM35A)

What quantification methods are most appropriate for TMEM35A expression analysis across different experimental systems?

For rigorous quantitative analysis:

• Western blot quantification:

  • Use recombinant standards for absolute quantification

  • Employ fluorescent secondary antibodies for wider linear detection range

  • Normalize to appropriate housekeeping controls verified in your experimental system

• Immunohistochemistry quantification:

  • Apply stereological principles for unbiased cell counting

  • Use automated image analysis software with standardized parameters

  • Incorporate internal reference standards in each experiment

• mRNA expression analysis:

  • Validate qPCR primers specifically for TMEM35A transcript variants

  • Use digital PCR for absolute quantification when possible

  • Select reference genes validated for stability in your experimental system

• Multi-method validation:

  • Correlate protein and mRNA expression data

  • Validate findings with both tagged and native protein detection methods

  • Consider single-cell approaches for heterogeneous tissues

How should researchers address specificity concerns when detecting low-abundance TMEM35A in complex tissue samples?

When working with low expression levels:

• Antibody validation hierarchy:

  • Demonstrate absence of signal in knockout/knockdown models

  • Show appropriate molecular weight detection (18.4 kDa)

  • Verify expected subcellular localization pattern

  • Confirm tissue expression pattern matching transcript data

• Technical approaches:

  • Implement signal amplification methods (TSA, HRP polymers)

  • Increase protein loading (up to 50-100 μg per lane)

  • Extend primary antibody incubation time (24-48 hours at 4°C)

  • Consider concentration steps before immunoprecipitation

• Control strategies:

  • Include side-by-side TMEM35A overexpression samples

  • Use peptide competition assays to verify signal specificity

  • Compare multiple antibodies recognizing different epitopes

What considerations are important when designing immunofluorescence experiments to co-localize TMEM35A with nAChRs?

For successful co-localization studies:

• Antibody compatibility:

  • Select primary antibodies raised in different host species

  • Validate each antibody individually before attempting co-localization

  • Test for potential cross-reactivity between secondary antibodies

• Technical optimization:

  • Fine-tune fixation protocol to preserve both membrane proteins

  • Optimize antigen retrieval specifically for transmembrane proteins

  • Employ sodium borohydride treatment to reduce tissue autofluorescence

• Imaging considerations:

  • Use confocal microscopy with appropriate controls for bleed-through

  • Consider super-resolution techniques for detailed subcellular localization

  • Implement Z-stack acquisition to capture the full spatial relationship

• Quantitative analysis:

  • Apply rigorous co-localization statistics (Pearson's, Manders' coefficients)

  • Establish objective thresholds for co-localization determination

  • Include appropriate positive and negative co-localization controls

How can researchers distinguish between specific and non-specific binding when using TMEM35A antibodies in brain tissue?

Discriminating between true and false signals requires:

• Sequential validation approach:

  • Block with peptide immunogen if available

  • Compare multiple antibodies against different epitopes

  • Correlate with mRNA expression data (ISH or RNA-seq)

  • Employ genetic knockout/knockdown controls when possible

• Technical controls:

  • Include secondary-only controls for each experiment

  • Implement appropriate blocking with 5% BSA or 5% normal serum

  • Titrate primary antibody to minimize background

  • Include absorption controls with excess antigen

• Data interpretation:

  • Be cautious of signals in regions with documented low mRNA expression

  • Verify subcellular localization pattern matches known biology (peroxisomes, ER)

  • Document unexpected signals and investigate systematically

  • Consider species differences when interpreting cross-reactivity

How can TMEM35A antibodies be utilized in disease model systems studying nicotinic receptor dysfunction?

TMEM35A antibodies offer valuable research tools for disease models:

• Neurodegenerative disease applications:

  • Monitor TMEM35A expression changes in Alzheimer's or Parkinson's models

  • Correlate with nAChR expression and localization alterations

  • Assess TMEM35A as a potential biomarker for cholinergic system dysfunction

• Methodological approaches:

  • Implement multiplexed immunofluorescence to simultaneously detect multiple components

  • Utilize proximity ligation assays to quantify TMEM35A-nAChR interactions

  • Apply TMEM35A immunoprecipitation followed by mass spectrometry to identify novel interaction partners

• Therapeutic implications:

  • Evaluate TMEM35A as a potential drug target for enhancing nAChR function

  • Use antibodies to monitor TMEM35A changes following experimental treatments

  • Develop phospho-specific antibodies if regulatory phosphorylation sites are identified

What approaches are recommended for studying TMEM35A in primary neuronal cultures versus tissue sections?

Different experimental systems require adapted methodologies:

• Primary neuron considerations:

  • Optimize fixation to preserve membrane protein epitopes (typically 4% PFA, 10-15 minutes)

  • Implement gentle permeabilization (0.1% Triton X-100 or 0.1% saponin)

  • Use developmental time-course studies to track expression changes

  • Correlate with functional nAChR assays at matching timepoints

• Tissue section approaches:

  • Adjust fixation protocols based on tissue preparation method (fresh-frozen vs. fixed)

  • Implement optimized antigen retrieval specific for transmembrane proteins

  • Consider thicker sections (40-100 μm) for 3D reconstruction of expression patterns

  • Use comparative region analysis to identify cell-type specificity

• Comparative analysis:

  • Document differences between in vitro and in vivo expression patterns

  • Validate key findings across multiple experimental systems

  • Consider the impact of culture conditions on TMEM35A expression and localization